An observational study in Obesity, sponsored by University Hospital, Toulouse. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-07-12.
Sponsored by University Hospital, Toulouse · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies in Obesity by University Hospital, Toulouse — 6 open to participants now, 6 under way, none of them phase 3. Obesity · University Hospital, Toulouse.
Among the 18 studies in Obesity by University Hospital, Toulouse, this one is one of 2 that started in 2022, is one of 3 observational ones, and was the 15th registered.
11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.
Browse Obesity studies →6 of the 18 studies in Obesity by University Hospital, Toulouse are open now, in 1 country. Recruiting first, the newest first:
University Hospital, Toulouse · Sites in France
Ages 18+
University Hospital, Toulouse · Sites in France
Ages 18–50 · Healthy volunteers
University Hospital, Toulouse · Sites in France
Ages 18–65
University Hospital, Toulouse · Sites in France
Ages 45–70 · Healthy volunteers
University Hospital, Toulouse · Sites in France
Ages 18–80
By country, each count listing its studies:
Of the 1,352 Obesity studies recruiting now, 382 (28%) set no upper age limit and 867 (64%) stop at 75 or younger; 169 take children under 18; 491 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
First in 2010; this study’s year is marked. 2 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 311 is above the median of 115 across 2,159 observational studies indexed under Obesity.
Median enrollment 38 across the 15 interventional studies, 170 across the 3 observational. Of the 12 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
University Hospital, Toulouse is the lead sponsor of 809 studies on the registry; 211 are open to participants now.
2 of the studies in Obesity by University Hospital, Toulouse that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05589688University Hospital, ToulouseIndividualization of Dosage Regimens in Obese Patients: Application to Acyclovir | 2026-12 |
| NCT07152990University Hospital, ToulousePrevalence of Nocturnal Hypoventilation in Obese Subjects Fiited With Continuous Positive Airway Pressure for Obstructive Sleep Apnea / Hypopnea Syndrome | 2027-05 |
Add all 2 to your calendar (.ics) → With an account.
Among the 18 studies in Obesity by University Hospital, Toulouse, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Obesity is recognized as a major public health problem. Recent research suggests the involvement of the gut microbiota in the development of obesity. Indeed, obese people are characterized by a dysbiotic intestinal microbiota. Periodontitis are chronic inflammatory oral pathologies linked to an imbalance between the bacterial etiological factor, oral dysbiosis, and the host's immune defenses.They lead to the destruction of the supporting tissues of the tooth and an apical migration of the periodontal attachment system, thus leading to the formation of the pathognomonic entity of the disease, the periodontal pocket.the presence of bacteria of oral origin such as Porphyromonas gingivalis (Pg) has been demonstrated in the adipose tissue of obese patients inducing a chronic low-grade inflammatory response by macrophages which leads to the proliferation of adipocyte precursors predisposing to obesity. The main objective is to assess the average amount of Porphyromonas gingivalis (Pg) in the saliva of obese people (BMI ≥ 30) with periodontitis.
Obesity is recognized as a major public health problem. Recent research suggests the involvement of the gut microbiota in the development of obesity. Indeed, obese people are characterized by a dysbiotic intestinal microbiota. Periodontitis are chronic inflammatory oral pathologies linked to an imbalance between the bacterial etiological factor, oral dysbiosis, and the host's immune defenses.They lead to the destruction of the supporting tissues of the tooth and an apical migration of the periodontal attachment system, thus leading to the formation of the pathognomonic entity of the disease, the periodontal pocket.the presence of bacteria of oral origin such as Porphyromonas gingivalis (Pg) has been demonstrated in the adipose tissue of obese patients inducing a chronic low-grade inflammatory response by macrophages which leads to the proliferation of adipocyte precursors predisposing to obesity. The main objective is to assess the average amount of Porphyromonas gingivalis (Pg) in the saliva of obese people (BMI ≥ 30) with periodontitis.This study is a comparative cross-sectional non-interventional study with retrospective and prospective and consecutive recruitment of participants.
Prospective patient recruitment:
During the patient's visit to the periodontology department, if the patient has periodontitis and has given his non-objection, he will be included in the study. A routine check-up in odontology will then be carried out: complete medical questionnaire (general, hygiene and dietetics), clinical examination (visual examination and statement of periodontal indices), radiological examination. Samples of saliva and periodontal plaque, conventionally taken in current dental surgery practice in the periodontal management of patients, will be used to carry out bacterial assays. CThe saliva samples, which are part of the usual treatment, will be carried out before and after the non-surgical periodontal treatment.
any patient coming for consultation in the periodontology department
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients with a body mass index superior or equal at 30 and with a periodontitis
Other: saliva samples
Patients with a body mass index inferior at 30 with a periodontitis
Other: saliva samples
Saliva samples, which are part of the usual treatment, will be carried out before and after the non-surgical periodontal treatment
Also known as: periodontal plaque samples
Analysis by bacterial culture and taxonomic analysis (MiSEQ) of the microbiological composition of saliva
Assess the microbiological composition of saliva and periodontal plaque in obese (BMI≥30) and non-obese (BMI\<30) patients with periodontitis.
Time frame: 8 weeks
Analysis by bacterial culture and taxonomic analysis (MiSEQ) of the microbiological composition periodontal plaque
Assess the microbiological composition of periodontal plaque in obese (BMI≥30) and non-obese (BMI\<30) patients with periodontitis.
Time frame: 8 weeks
Plan to share: No
No publications or documents are linked to this record.
Started Dec 2022 (actual). Primary completion is estimated for Mar 2024, 15 months after the start.
Of 796 non-industry observational studies under Obesity, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 106. This study's planned 15 months is below that.
Counting every sponsor, half of 842 studies reached it within 39 months; a quarter within 17 and three quarters within 96.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Hospital, Toulouse →